RMTI · Rockwell Medical, Inc.
Market Cap
$33.73M
Shares
4.03M
Volume · Oct 5
10.06K
Avg daily vol (3M)
27.5K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.65
Open$8.51
Day$8.50–8.73
52W close$5.19–12.60
Avg vol 30d21K
Short int90K · 2.2% float · 4.6d
Short vol50%
Last earningsAug 13, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 15, 2026
Est · unconfirmed
· in 6 wks
filed Aug 13, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$69.39M
Trailing 12 months
Net income (TTM)
−$5.08M
Trailing 12 months
Revenue growth YoY
+10.6%
Year over year
Operating margin
-6.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
4.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.52M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+15.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
2.2%
Latest settlement · 4.6 days to cover
AI Brief
Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26
TL;DR. Rockwell Medical reported Q2 2026 net sales of $17.8M, up 11% year-over-year, with gross margin expanding to 18% and $2.1M of operating cash flow, while reiterating full-year guidance of $70–75M in net sales, 18–22% gross margin, and $1–2M adjusted EBITDA.
Bullish
- + Q2 net sales rose 11% year-over-year to $17.8M on new western U.S. customers and higher existing-customer volumes.
- + Gross profit grew 30% year-over-year and gross margin expanded to 18% from 16% on lower manufacturing costs and higher volume.
- + Generated $2.1M of cash from operations in Q2, lifting cash and investments to $24.8M.
- + New Heritage Dialysis agreement and renewed aQua Dialysis agreement extend recurring revenue base with annual pricing provisions.
- + Net loss narrowed to $1.2M in Q2 from $1.5M a year ago and $1.6M in Q1 2026.
Bearish
- − First-half 2026 net sales were essentially flat year-over-year at $35.1M vs $35.0M, with growth masked by prior-year DaVita volume.
- − Adjusted EBITDA remained negative at $(0.2)M in Q2, flat year-over-year, signaling profitability goals still distant.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+3%
above
Price vs 50-day avg
+11%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
47%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+8%
trailing
6-month return
−8%
trailing
YTD return
+4%
this year
Relative strength
−20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow
Distributing
-14% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.23% of float · ▼ -3.3% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
37 holders — mid 3-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
−32%
Y/Y
Gross margin
17%
contracting
EPS growth
−400%
Y/Y
Balance sheet
$1.9M
net cash
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 13, 2026
Net Sales
· 2026 Annual Guidance
Initiated
$70M – $75M
prior FY $69.26M
midpoint +4.7% Y/Y
Gross Margin
· 2026 Annual Guidance
Initiated
18% – 22%
Adjusted EBITDA
· 2026 Annual Guidance
Non-GAAP
Initiated
$1M – $2M
Guided vs delivered
· last 3 settled
Net sales
2023
guided $82M – $86M
$83.61M
In line
Net sales
third quarter 2023
guided $21M – $23M
$23.77M
Beat +8.1%
Total annual revenue
2022
guided $65M – $70M
$72.81M
Beat +7.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+3%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
47%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow
Distributing
-14% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.23% of float · ▼ -3.3% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
37 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $9 · 47%
Range high $13
vs 200-day avg +3%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$0.4M | Six Months Ended June 30, 2026 | — |
| Adjusted EPS non-GAAP | -$0.11 | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RMTI
this stock
Rockwell Medical, Inc.
|
$33.73M | — | -31.8% | — | 2.2% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RMTI | +3.4% | +8.3% | -8.0% | +1.3% | +4.2% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +3.6% | +8.8% | -20.2% | +0.4% | -8.6% |